Clinical trial · Interventional
Yang Yin Fu Zheng Jie Du Therapy in Recurrence of Hepatocellular Carcinoma Less Than 3 cm in Diameter
NCT04264962CI-TRIAL-00054415YYFZJDTRHCLT3DcompletedEarly Phase 1ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Clinical research of Yang Yin Fu Zheng Jie Du therapy in recurrence of Hepatocellular Carcinoma less than 3 cm in diameter.The purpose of this study is to observe the efficacy of routine medical care combined with Yang Yin Fu Zheng Jie Du therapy in 1 year recurrence for patients belong to Hepatocellular Carcinoma less than 3 cm in diameter.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Hepatocellular Carcinoma | Hepatocellular Carcinoma | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Routine medical care | Other | — | UNRESOLVED |
| Yang Yin Fu Zheng Jie Du therapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Yang Yin Fu Zheng Jie Du therapy
- interventionNames
- Drug: Yang Yin Fu Zheng Jie Du therapy
- Other: Routine medical care
- type
- PLACEBO_COMPARATOR
- label
- Routine medical care
- interventionNames
- Other: Routine medical care
Primary outcomes (1)
- measure
- Recurrance rate
- timeFrame
- 1 year
Secondary outcomes (2)
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Meet the criteria of hepatocellular carcinoma * Ages Eligible for Study: ≤75 years old; * The size of the main nodule and multi-centricity (single lesion, three nodules ≤3 cm) * After transarterial chemoembolisation (TACE) or radiofrequency ablation (RFA) * Surgery cannot be allowed; * Informed consent from the patient. Exclusion Criteria: * Serious problem of heart, lung, or kidney with severe dysfunction; * Pregnant or child breast feeding women; * Mental or cognitive disorders; * Participating in other drug trials; * Who are allergic to the study drug.
References
Publications (1)
- DERIVEDYan H, Wang X, Liu X, Yu L, Xie Y, Wu T, Jiang Y, Yang Z. Yangyin Fuzheng Jiedu prescription as an adjunct to minimally invasive treatment in early-stage hepatocellular carcinoma: a randomized controlled trial. Front Pharmacol. 2026 Jul 6;17:1780139. doi: 10.3389/fphar.2026.1780139. eCollection 2026. PMID 42518346